Procter & Gamble Co.

PG
NYSEFree primer · Steps 1–3 of 21Updated May 12, 2026Coverage as of 2026-Q2
TTM ROIC
17%FY2025
Moat
Wide
Latest Q Revenue
$19.8B+0% YoYQ3 FY2026
Top Holder
Vanguard9.5%
Institutional
72.5%
Bull Case
Sustainable volume recovery and tariff normalization, combined with a new CEO productivity program, could drive meaningfully stronger organic growth and margin expansion.
Bear Case
Retailer restocking flatters organic growth while private label secular share gains and persistent tariff headwinds structurally suppress volume and compress P&G's valuation multiple.

Business Model


ticker: PG step: 01 generated: 2026-05-11 source: quick-research

The Procter & Gamble Company (PG) — Business Overview

Business Description

Procter & Gamble is the world's largest consumer packaged goods company by revenue, with an iconic portfolio of household and personal-care brands spanning fabric care, home care, baby/feminine/family care, beauty, grooming, and health care. P&G operates on a "superiority" strategy — invest in premium product performance, packaging, brand communication, retail execution, and value — to defend pricing power and capture share against private label.

Revenue Model

  • Fabric & Home Care (~36% of revenue): Detergents, dish, surface care
  • Baby, Feminine & Family Care (~24%): Diapers, period care, paper towels, toilet paper
  • Beauty (~18%): Hair care, skin care, deodorants
  • Health Care (~14%): Oral care, personal health (cold/flu, digestive)
  • Grooming (~8%): Razors, shaving products
  • Mostly mature category growth driven by mix shift to premium tiers + emerging market expansion

Products & Services

  • Fabric & Home Care: Tide, Ariel, Downy, Gain, Cascade, Dawn, Fairy, Febreze, Mr. Clean, Swiffer
  • Baby/Feminine/Family Care: Pampers, Luvs, Always, Tampax, Bounty, Charmin, Puffs
  • Beauty: Pantene, Head & Shoulders, Olay, SK-II, Old Spice, Secret, Native, Herbal Essences
  • Health Care: Crest, Oral-B, Vicks, Metamucil, Pepto-Bismol, Neurobion
  • Grooming: Gillette, Venus, Braun
  • 21+ "billion-dollar brands" generating $1B+ in annual sales each

Customer Base & Go-to-Market

  • Retail customers: Mass retailers (Walmart, Target, Costco, Amazon), drug chains, grocery, club, e-commerce — P&G's top 10 customers are ~40% of sales
  • End consumers: ~5B+ global consumers across 180+ countries
  • B2B: Some hospital and institutional sales (e.g., Tampax to hospitals)
  • Channel mix: Mass + grocery dominant; e-commerce now ~17% of sales and growing

Competitive Position

P&G's primary moats: (1) brand equity built over decades of advertising — many P&G brands have 60%+ category mindshare in their categories; (2) global scale provides advertising, R&D, and supply chain efficiencies private-label and smaller competitors can't match; (3) "superiority" execution discipline keeps premium price tiers defendable; (4) retailer relationships (P&G is often the largest CPG vendor for major retailers). Faces structural pressure from private label (especially in fabric care and family care), the "GLP-1 effect" on snacking-adjacent categories (less direct exposure than Mondelez/Hershey but indirect via reduced retailer foot traffic), and emerging-market FX volatility.

Key Facts

  • Founded: 1837 (William Procter + James Gamble in Cincinnati)
  • Headquarters: Cincinnati, OH
  • Employees: ~108,000
  • Exchange: NYSE
  • Sector / Industry: Consumer Staples / Household Products
  • Market Cap: ~$355B (May 2026)
  • CEO: Jon Moeller (CEO transition announced — Shailesh Jejurikar to succeed in 2026)
  • Dividend: $4.20+ annual; 68+ consecutive years of dividend growth (Dividend King)
  • FY end: June

Financial Snapshot


ticker: PG step: 04 generated: 2026-05-11 source: quick-research

The Procter & Gamble Company (PG) — Financial Snapshot

Note: P&G's fiscal year ends in June. "FY2025" below = fiscal year ended June 30, 2025.

Income Statement Summary

Metric FY2023 FY2024 FY2025 YoY
Net Sales $82.0B $84.0B $84.3B flat
Organic Sales Growth +7% +4% +2% decelerating
Gross Margin 49.0% 51.6% 52.0% +0.4pp
Operating Margin 22.0% 24.0% 24.5% +0.5pp
Net Income $14.7B $14.9B $15.5B +4%
Core EPS (diluted) $5.90 $6.59 $6.85 +4%

Q3 FY2026 Highlights (most recent reported, Jan-Mar 2026)

Metric Q3 FY26 YoY
Net Sales $21.1B +3%
Organic Sales +3% (2% volume, 1% price)
Core EPS $1.59
Adj. FCF Productivity 82%

Segment Performance Q1 FY26 (most relevant)

Segment Organic Growth Volume Notes
Beauty +6% +5% Olay, Pantene drove
Health Care +3% +2% Crest, Oral-B
Grooming +2% flat Pricing-led
Fabric & Home Care +2% +2% Tide volume strong
Baby/Feminine/Family flat +3% (offset by -10% Family Care vol from tariff front-loading)

Cash Flow & Balance Sheet (FY2025)

Metric Value
Cash Flow from Operations $19.8B
Capital Expenditures ~($3.8B)
Free Cash Flow ~$16.0B
FCF Productivity (% of Net Income) 103%
Cash & Investments ~$10B
Total Debt ~$33B

Key Ratios (approximate, May 2026)

  • P/E (forward): ~22x | EV/EBITDA: ~17x | Dividend Yield: ~2.6%
  • ROE: ~30%+ | ROIC: ~17%
  • FCF Yield: ~4.5%
  • Net Debt / EBITDA: ~1.0x

Growth Profile

P&G is in slow-grow territory: FY2025 organic sales +2% (vs. multi-year average ~4-5%), driven by 2% volume and 1% pricing. The pricing fortress (52% gross margin, 24.5% operating margin) remains intact via the "superiority" strategy, but volume in core categories (Family Care -10%) is showing strain from $1B+ tariff costs and consumer trade-down to private label in certain commoditized SKUs. Beauty is the growth bright spot at +6% organic.

Forward Estimates

  • FY2026E Net Sales: ~$87B (+3%)
  • FY2026E Core EPS: ~$6.85-7.10 (consensus, +1-3%)
  • FY2026E FCF: ~$16-17B
  • FY2027E EPS: ~$7.40 (consensus, +5-7%)

Capital Return

  • Dividend $4.20+ annual ($10B+ paid annually) — 68 consecutive years of increases (Dividend King)
  • Share buybacks: $7-9B annual run-rate
  • Total capital return: ~$17-20B annual
  • Long-term target: 60% of earnings as dividend, balance as buybacks

Recent Catalysts


ticker: PG step: 12 generated: 2026-05-11 source: quick-research

The Procter & Gamble Company (PG) — Investment Catalysts & Risks

Bull Case Drivers

  1. Pricing fortress + premiumization defending margins — Despite organic growth decelerating to 2-3%, gross margin expanded to 52% and operating margin to 24.5% in FY25. The "superiority" strategy (premium product / better performance) is allowing P&G to hold price even as private label gains share in some commodity SKUs. New premium launches in 2026 — Pampers AMORE, Swiffer PowerMop upgrades, BEVEL body cream, premium Dawn — extend this playbook.

  2. GLP-1 insulation via hygiene/baby/grooming exposure — Unlike Hershey, Mondelez, Pepsi (where GLP-1 weight-loss drug adoption directly reduces snack consumption), P&G's portfolio is concentrated in daily-use hygiene, baby care, fabric care, and grooming — categories largely independent of dietary changes. P&G is one of the few CPG companies with limited GLP-1 exposure.

  3. Dividend King status (68 consecutive years of increases) — One of only a handful of Dividend Kings, ~$10B annual dividend at 60%+ payout ratio. Combined with ~$8B buybacks, P&G returns ~$18-20B annually = ~5% combined yield. The dividend track record gives PG a "bond-like" institutional bid even in a low-growth environment.

  4. Beauty acceleration (Q1 FY26 +6% organic) — Olay, Pantene, Head & Shoulders, SK-II, Native are driving outsized growth in skin and hair care. Premium beauty has stronger pricing power than commoditized fabric/family care; if Beauty continues at 6%+, it can lift blended growth toward 4%+ over time.

Bear Case Risks

  1. $1B+ tariff headwind + Family Care volume drop — New 2026 tariffs added ~$1B to cost base. Family Care volume dropped 10% YoY in Q1 FY26, attributed to consumers front-loading purchases in late 2025 to beat the January 1 tariff schedule. If tariffs persist and PG can't fully price through, margin compresses materially.

  2. Private label encroachment — In fabric care and family care specifically, retailer-brand competitors (Costco's Kirkland, Walmart's Great Value, Amazon Basics) have improved quality and won shelf space. P&G volume in commoditized SKUs (Bounty, Charmin in some channels) faces structural pressure even at premium price tiers.

  3. Slow organic growth (~2-3%) at premium multiple — Stock trades at ~22x forward EPS with FY26 EPS growth of only +1-3%. PEG ~5x+. If the U.S. consumer downshifts further or emerging-market FX weakens, missing already-low estimates could trigger meaningful multiple compression on a "Dividend King premium" that bears argue is unjustified.

  4. CEO transition risk — Jon Moeller stepping down; Shailesh Jejurikar (current COO, longtime P&G insider) taking over in 2026. Even with internal succession, a multi-year strategic refresh under new leadership can introduce execution risk during sluggish growth.

Upcoming Events

  • Q4 FY26 earnings (July 2026) — Tariff impact full quarterly run-rate; FY27 organic growth/EPS guidance
  • Jejurikar formal CEO start — TBD 2026 — first capital allocation/strategy update
  • Annual Investor Day 2026 — Long-term algorithm, premium portfolio review
  • Cost productivity programs — Multi-year $1.5B savings initiatives offsetting tariffs
  • Q1 FY27 earnings (October 2026) — First full quarter under new CEO; back-to-school + flu-season volume signal

Analyst Sentiment

Sell-side consensus is Hold / Buy with average price targets in the $165-175 range vs. recent ~$152 trading levels. Bulls cite the pricing fortress, GLP-1 insulation, and 68-year dividend track record. Bears focus on the premium 22x multiple, organic growth deceleration, tariff cost pressure, and private label encroachment in commoditized categories.

Research Date

Generated: 2026-05-11

Full Research Available

This primer covers steps 1–3 of 21. The full deep dive includes moat analysis, DCF valuation, bull/bear scenarios, management quality, earnings transcript analysis, competitive positioning, returns on capital, institutional/insider activity, and an investment memo.

View Investment MemoEach memo is $2. Coverage subscriptions for funds coming soon — join the waitlist.